S-1/A: Calidi Biotherapeutics Announces Proposed Offering of Common Stock and Warrants

Calidi Biotherapeutics plans to offer common stock units and pre-funded warrant units, along with associated warrants, aiming to raise capital for working capital and general corporate purposes.

Summary

• Calidi Biotherapeutics is planning an offering of up to 19,047,619 common stock units, each including one share of common stock, a Series A warrant, a Series B warrant, and a Series C warrant.
• The company is also offering pre-funded warrant units (up to 19,047,619), each including a pre-funded warrant, a Series A warrant, a Series B warrant, and a Series C warrant, as an alternative for purchasers who would exceed beneficial ownership limitations.
• The assumed purchase price for each common stock unit is $0.42, which was the last sale price of the company's common stock on April 4, 2024.
• The warrants have an initial exercise price of $0.42 per share, subject to adjustment on the earlier of a stock split or 90 days after the offering's closing.
• Ladenburg Thalmann & Co., Inc. is acting as the exclusive placement agent for the offering.
• The offering will terminate on April 30, 2024, unless terminated earlier at the company's discretion.
• Net proceeds will be used for working capital and general corporate purposes.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced disclosure requirements.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, outlining the terms of a proposed securities offering. While the offering itself could be seen as a positive step for the company's financial health, the document also acknowledges the risks involved and the company's need for additional funding. Therefore, the sentiment is neutral to slightly positive.

Positives

• The offering aims to strengthen the company's financial position.
• The company has engaged a placement agent to assist with the offering.
• The company has flexibility in allocating the net proceeds.

Negatives

• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• The company is an emerging growth company and a smaller reporting company, which may result in less information being available to investors.
• There is no established trading market for the Pre-Funded Warrants or Common Warrants and we do not expect a market to develop.

Risks

• Investing in the company's securities involves a high degree of risk.
• The company is an immuno-oncology company with a limited operating history and has not generated any revenue to date from product sales.
• The company needs to raise substantial additional funding.
• The company's market is thinly traded which may adversely affect the liquidity and price of our securities.
• The price of the company's stock may be volatile, which could result in substantial losses for investors.
• If the company fails to comply with the continued listing standards of the NYSE American, its common stock could be delisted.
• The Sponsor, Metric, anchor investors and other investors purchased or received as an inducement to facilitate the Business Combination the Sponsor Shares that were acquired by the Sponsor, Metric or anchor investors at $0.004 per share price which is significantly below the current market price of a share of our common stock and such holder could sell their shares and generate a significant profit while causing the trading price of our common stock to decline significantly.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, and pre-clinical and clinical trials.

Industry Context

The document indicates a capital-raising activity in the immuno-oncology sector, where companies are continuously seeking funds for research, development, and clinical trials. The offering is structured to accommodate investors with beneficial ownership limitations, a common practice in the industry.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's financial position may be strengthened by the capital raised.
• The company's ability to fund research and development may be enhanced.

Next Steps

• The company will proceed with the offering, seeking to sell the securities to investors.
• The company will file the final prospectus with the SEC.
• The company will use the net proceeds for working capital and general corporate purposes, and pre-clinical and clinical trials.

Key Dates

Keywords

common stock, warrants, offering, securities, Calidi Biotherapeutics, pre-funded warrants, placement agent, units, exercise price, beneficial ownership